Breaking the $100M Barrier: How Biotech CEOs Closed Mega-Rounds in a Tough Market

In an increasingly selective capital environment, a handful of biotech CEOs have managed to defy the odds—closing $100 million-plus financing rounds that fueled major growth, platform expansion, and pipeline acceleration. What separates these companies from the rest? What messages, metrics, and milestones resonate most with investors in today’s market? This session brings together biotech CEOs who have each raised $100M+ rounds to share the behind-the-scenes stories of how they did it—what worked, what didn’t, and what they’d do differently next time. From crafting a compelling narrative and building investor confidence to navigating syndicate dynamics and valuation pressure, the discussion will offer actionable insights for founders preparing their next raise.